BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 30418193)

  • 1. Hydroxychavicol sensitizes imatinib-resistant chronic myelogenous leukemia cells to TRAIL-induced apoptosis by ROS-mediated IAP downregulation.
    Paul T; Banerjee A; Reddy SVB; Mahato SK; Biswas N
    Anticancer Drugs; 2019 Feb; 30(2):167-178. PubMed ID: 30418193
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hydroxychavicol sensitizes imatinib-resistant chronic myelogenous leukemia cells to TRAIL-induced apoptosis by ROS-mediated IAP downregulation: Erratum.
    Anticancer Drugs; 2024 Apr; 35(4):383. PubMed ID: 38451676
    [No Abstract]   [Full Text] [Related]  

  • 3. Sensitization of imatinib-resistant CML cells to TRAIL-induced apoptosis is mediated through down-regulation of Bcr-Abl as well as c-FLIP.
    Park SJ; Kim MJ; Kim HB; Kang CD; Kim SH
    Biochem J; 2009 Apr; 420(1):73-81. PubMed ID: 19203346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hydroxychavicol, a Piper betle leaf component, induces apoptosis of CML cells through mitochondrial reactive oxygen species-dependent JNK and endothelial nitric oxide synthase activation and overrides imatinib resistance.
    Chakraborty JB; Mahato SK; Joshi K; Shinde V; Rakshit S; Biswas N; Choudhury Mukherjee I; Mandal L; Ganguly D; Chowdhury AA; Chaudhuri J; Paul K; Pal BC; Vinayagam J; Pal C; Manna A; Jaisankar P; Chaudhuri U; Konar A; Roy S; Bandyopadhyay S
    Cancer Sci; 2012 Jan; 103(1):88-99. PubMed ID: 21943109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. H
    Paul T; Roy R; Sarkar RD; Sinha S; Biswas N
    Free Radic Biol Med; 2021 Apr; 166():265-276. PubMed ID: 33631302
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cotreatment with STI-571 enhances tumor necrosis factor alpha-related apoptosis-inducing ligand (TRAIL or apo-2L)-induced apoptosis of Bcr-Abl-positive human acute leukemia cells.
    Nimmanapalli R; Porosnicu M; Nguyen D; Worthington E; O'Bryan E; Perkins C; Bhalla K
    Clin Cancer Res; 2001 Feb; 7(2):350-7. PubMed ID: 11234890
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exploitation of redox discrepancy in leukemia cells by a reactive oxygen species nanoscavenger for inducing cytotoxicity in imatinib resistant cells.
    Acharya S; Sahoo SK
    J Colloid Interface Sci; 2016 Apr; 467():180-191. PubMed ID: 26802277
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergistic apoptosis of CML cells by buthionine sulfoximine and hydroxychavicol correlates with activation of AIF and GSH-ROS-JNK-ERK-iNOS pathway.
    Chowdhury AA; Chaudhuri J; Biswas N; Manna A; Chatterjee S; Mahato SK; Chaudhuri U; Jaisankar P; Bandyopadhyay S
    PLoS One; 2013; 8(9):e73672. PubMed ID: 24040019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of Concern: Hydroxychavicol, a Piper betle leaf component, induces apoptosis of CML cells through mitochondrial reactive oxygen species-dependent JNK and endothelial nitric oxide synthase activation and overrides imatinib resistance.
    Cancer Sci; 2024 Jun; 115(6):2086. PubMed ID: 38538295
    [No Abstract]   [Full Text] [Related]  

  • 10. Effect of the XIAP inhibitor Embelin on TRAIL-induced apoptosis of pancreatic cancer cells.
    Mori T; Doi R; Kida A; Nagai K; Kami K; Ito D; Toyoda E; Kawaguchi Y; Uemoto S
    J Surg Res; 2007 Oct; 142(2):281-6. PubMed ID: 17640673
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BCR-ABL-mediated upregulation of PRAME is responsible for knocking down TRAIL in CML patients.
    De Carvalho DD; Binato R; Pereira WO; Leroy JM; Colassanti MD; Proto-Siqueira R; Bueno-Da-Silva AE; Zago MA; Zanichelli MA; Abdelhay E; Castro FA; Jacysyn JF; Amarante-Mendes GP
    Oncogene; 2011 Jan; 30(2):223-33. PubMed ID: 20838376
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ABT-737 increases tyrosine kinase inhibitor-induced apoptosis in chronic myeloid leukemia cells through XIAP downregulation and sensitizes CD34(+) CD38(-) population to imatinib.
    Airiau K; Mahon FX; Josselin M; Jeanneteau M; Turcq B; Belloc F
    Exp Hematol; 2012 May; 40(5):367-78.e2. PubMed ID: 22240609
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Persistent STAT5-mediated ROS production and involvement of aberrant p53 apoptotic signaling in the resistance of chronic myeloid leukemia to imatinib.
    Cheng Y; Hao Y; Zhang A; Hu C; Jiang X; Wu Q; Xu X
    Int J Mol Med; 2018 Jan; 41(1):455-463. PubMed ID: 29115375
    [TBL] [Abstract][Full Text] [Related]  

  • 14. XIAP inhibition and generation of reactive oxygen species enhances TRAIL sensitivity in inflammatory breast cancer cells.
    Allensworth JL; Aird KM; Aldrich AJ; Batinic-Haberle I; Devi GR
    Mol Cancer Ther; 2012 Jul; 11(7):1518-27. PubMed ID: 22508521
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medicarpin, a legume phytoalexin sensitizes myeloid leukemia cells to TRAIL-induced apoptosis through the induction of DR5 and activation of the ROS-JNK-CHOP pathway.
    Trivedi R; Maurya R; Mishra DP
    Cell Death Dis; 2014 Oct; 5(10):e1465. PubMed ID: 25321472
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Simultaneous targeting of P-gp and XIAP with siRNAs increases sensitivity of P-gp overexpressing CML cells to imatinib.
    Seca H; Lima RT; Guimarães JE; Helena Vasconcelos M
    Hematology; 2011 Mar; 16(2):100-8. PubMed ID: 21418741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of XIAP in resistance to TNF-related apoptosis-inducing ligand (TRAIL) in Leukemia.
    Saraei R; Soleimani M; Movassaghpour Akbari AA; Farshdousti Hagh M; Hassanzadeh A; Solali S
    Biomed Pharmacother; 2018 Nov; 107():1010-1019. PubMed ID: 30257312
    [TBL] [Abstract][Full Text] [Related]  

  • 18. miR-101 sensitizes K562 cell line to imatinib through Jak2 downregulation and inhibition of NF-κB target genes.
    Farhadi E; Zaker F; Safa M; Rezvani MR
    Tumour Biol; 2016 Oct; 37(10):14117-14128. PubMed ID: 27517565
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PBA2, a novel inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia.
    Gupta P; Kathawala RJ; Wei L; Wang F; Wang X; Druker BJ; Fu LW; Chen ZS
    Cancer Lett; 2016 Dec; 383(2):220-229. PubMed ID: 27720778
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cotreatment with apicidin overcomes TRAIL resistance via inhibition of Bcr-Abl signaling pathway in K562 leukemia cells.
    Park SJ; Kim MJ; Kim HB; Sohn HY; Bae JH; Kang CD; Kim SH
    Exp Cell Res; 2009 Jul; 315(11):1809-18. PubMed ID: 19268463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.